R
Raymond F. Suckow
Researcher at Columbia University
Publications - 44
Citations - 2005
Raymond F. Suckow is an academic researcher from Columbia University. The author has contributed to research in topics: Ketamine & Dopaminergic. The author has an hindex of 22, co-authored 44 publications receiving 1813 citations. Previous affiliations of Raymond F. Suckow include Nathan Kline Institute for Psychiatric Research & University of York.
Papers
More filters
Journal ArticleDOI
Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers.
Eric Hollander,Concetta M. DeCaria,Anca Nitescu,Robert Gully,Raymond F. Suckow,Thomas B. Cooper,Jack M. Gorman,Donald F. Klein,Michael R. Liebowitz +8 more
TL;DR: Behavioral and neuroendocrine responses appeared divergent in patients following m-CPP but not following fenfluramine, and complex mechanisms involving multiple neurotransmitter and neuromodulator systems are suggested.
Journal ArticleDOI
High dose D-serine in the treatment of schizophrenia
Joshua T. Kantrowitz,Anil K. Malhotra,Barbara A. Cornblatt,Gail Silipo,Andrea Balla,Raymond F. Suckow,Cyril D'Souza,John R. Saksa,Scott W. Woods,Daniel C. Javitt +9 more
TL;DR: Findings support double-blind investigation of D-serine at doses> or =60 mg/kg/d, and suggest effectiveness in treatment of both persistent symptoms and neurocognitive dysfunction.
Journal ArticleDOI
Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans.
John H. Krystal,Laurence P. Karper,A. Bennett,Deepak Cyril D'Souza,Anissa Abi-Dargham,K. Morrissey,Abi-Saab D,J. D. Bremner,M. B. Bowers,Raymond F. Suckow,Stetson P,George R. Heninger,Dennis S. Charney +12 more
TL;DR: Data suggest that subhypnotic lorazepam and ketamine show a spectrum of interactive effects, ranging from antagonism to potentiation.
Journal ArticleDOI
Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chloro-phenylpiperazine in obsessive-compulsive disorder
Eric Hollander,Concetta M. DeCaria,Robert Gully,Anca Nitescu,Raymond F. Suckow,Jack M. Gorman,Donald F. Klein,Michael R. Liebowitz +7 more
TL;DR: Chronic fluoxetine treatment diminished the behavioral sensitivity to mCPP and did not diminish, but may have partially normalized, the neuroendocrine response to m CPP in patients with OCD, suggesting adaptive homeostatic effects may reflect fluoxettine's antiobsessional mechanism.
Journal ArticleDOI
A pilot in vivo proton magnetic resonance spectroscopy study of amino acid neurotransmitter response to ketamine treatment of major depressive disorder.
Matthew S. Milak,C J Proper,Stephanie T. Mulhern,A L Parter,Lawrence S. Kegeles,R.T. Ogden,Xiangling Mao,Carolyn I. Rodriguez,Maria A. Oquendo,Raymond F. Suckow,Thomas B. Cooper,John G. Keilp,Dikoma C. Shungu,J. John Mann +13 more
TL;DR: The N-methyl-D-aspartate receptor antagonist ketamine can improve major depressive disorder (MDD) within hours and clinical improvement correlated with 90-min norketamine concentration, but no other measures were found.